Skip to main content

Table 1 Patient characteristics in training(n = 143) and validation cohorts(n = 61)

From: Development and validation a radiomics combined clinical model predicts treatment response for esophageal squamous cell carcinoma patients

 

Training Cohort

Validation Cohort

P values

Clinical characteristic

   

Age (years, median-range)

61 (39 ~ 78)

61 (44 ~ 79)

0.903

Gender (Male/Female)

115/28

48/13

0.778

ECOG PS

  

0.625

PS = 0

71

28

 

PS ≥ 1

72

33

 

Tumor location

  

0.129

Cervical

16

12

 

Upper

53

22

 

Middle

54

22

 

Lower

20

5

 

Differentiation

  

0.482

Well

71

27

 

Intermediate/ Poorly

72

34

 

T stage

  

0.478

T1-T2

16

9

 

T3-T4

127

52

 

N stage

  

0.335

N0

24

7

 

N+

119

54

 

M stage

  

0.334

M0

111

51

 

M1

32

10

 

Therapeutic model

  

0.139

CCRT-C

33

17

 

I-CCRT

11

8

 

I-CCRT-C

26

12

 

SCRT

73

24

 

Radiotherapy technology

  

0.375

3D-CRT

47

24

 

IMRT

96

37

 

Radiotherapy dose (Gy)

  

0.838

< 60

49

20

 

≥ 60

94

41

 

Chemotherapy plan

  

0.991

DP

96

41

 

PF

47

20

 

Chemotherapy cycles

  

0.721

4–5

90

40

 

6–8

53

21

 

The hematology test results

   

CEA (ng/ml)

  

0.195

< 3.4

119

46

 

≥ 3.4

24

15

 

Cyfra21(ng/ml)

  

0.489

< 3.3

106

48

 

≥ 3.3

37

13

 

Treatment response

  

0.301

OR

100

47

 

Non-OR

43

14

 
  1. Continued Table 1. ECOG PS: Eastern cooperative oncology group performance status; 3D-CRT: three-dimensional conformal radiotherapy; IMRT: Intensity modulated radiotherapy; DP: cisplatin plus docetaxel; PF: cisplatin plus fluorouracil; OR: Objective response;
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us